In vivo, H3B-5942 has shown antitumor activity as a single agent in BC xenograft models with ESR1 wild-type and harboring ESR1 Y537S mutations that was superior to fulvestant treatment [71]. This evidence concerns the gene ESR1 and breast cancer.